icone plus
Contact Abonnez-vous aux actualités
Reason for request
Extension of indication
Clinical Benefit
Clinical Added Value
no clinical added value
EYLEA does not provide any improvement in actual benefit (level V, non-existent) compared with LUCENTIS for adults in the treatment of visual impairment due to macular oedema secondary to central retinal vein occlusion (CRVO).
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
7dYkkVmwEG88tPqM
Listen
